Key result
Pravastatin provides an absolute ~28% CV event reduction in TLR4 299Gly carriers.
RCT (n=655)
Placebo-controlled
Randomly assigned
Answers are grounded in this paper and cite their sources.
Randomized trial demonstrates that TLR4 Asp299Gly enhances pravastatin benefit in men with coronary artery disease, suggesting genetic moderation of cardiovascular risk.
BACKGROUND: Atherosclerosis is increasingly considered to be a chronic inflammatory process. We examined whether genetic variants of the toll-like receptor 4 (TLR4), which are correlated with impaired innate immunity and with progression of carotid atherosclerosis, are also associated with coronary atherosclerosis and predict the risk of cardiovascular events. METHODS AND RESULTS: Two polymorphisms of the TLR4 gene (Asp299Gly and Thr399Ile) were determined in 655 men with angiographically documented coronary atherosclerosis. All patients participated in a prospective cholesterol-lowering trial evaluating the effect on coronary artery disease and were randomly assigned to either pravastatin or placebo for 2 years. There were no significant differences between genetically defined subgroups with respect to baseline risk factors, treatment, or in-trial changes of lipid, lipoprotein, or angiographic measurements. Genotype was not associated with progression of atherosclerosis. In the pravastatin group, 299Gly carriers had a lower risk of cardiovascular events during follow-up than noncarriers (2.0% versus 11.5%, P=0.045). Among noncarriers, pravastatin reduced the risk of cardiovascular events from 18.1% to 11.5% (P=0.03), whereas among 299Gly carriers this risk was strikingly reduced from 29.6% to 2.0% (P=0.0002, P=0.025 for interaction). CONCLUSIONS: Among symptomatic men with documented coronary artery disease, the TLR4 Asp299Gly polymorphism was associated with the risk of cardiovascular events. This variant also modified the efficacy of pravastatin in preventing cardiovascular events, such that carriers of the variant allele had significantly more benefit from pravastatin treatment.
No takes yet. Share an insight, caveat, or question.
Boekholdt et al. (2003) conducted an RCT in Coronary atherosclerosis (n=655). Pravastatin (stratified by TLR4 Asp299Gly polymorphism) vs. Placebo (and TLR4 Asp299Gly noncarriers) was evaluated on Cardiovascular events (in TLR4 299Gly carriers) (p=0.0002 (P=0.025 for interaction)). Pravastatin reduced cardiovascular events more in TLR4 299Gly carriers than noncarriers.
Synapse has enriched 10 related papers. Consider them for comparative context: